Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Transfusion burden among older US patients with relapsed FLT3-mutated Acute Myeloid Leukemia treated with gilteritinib: A Medicare claims-based cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

TLThomas LeblancABAlana BlockCYChristopher Young

Discussion

Loading...

Member takes

Overview

Cohort study shows gilteritinib improves transfusion independence in older AML patients, suggesting reduced transfusion burden.

Key Points

  • This research aims to characterize transfusion burden among older Medicare beneficiaries with relapsed AML treated with gilteritinib.
  • Retrospective observational cohort study using Medicare claims data.
  • Analyzed patients aged ≥65 years with confirmed relapsed AML and gilteritinib prescriptions.
  • Evaluated transfusion independence based on a continuous 56-day period without transfusions.
  • Among 169,642 Medicare beneficiaries with AML, 962 were eligible and 799 initiated gilteritinib.
  • 56% of patients were transfusion independent for red blood cells prior to treatment initiation.
  • At ≥8 weeks, 63.9% achieved red blood cell transfusion independence, indicating significant improvement.

Cite This Study

Leblanc et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e39ehttps://doi.org/10.1182/blood-2025-1664
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations2026
  2. 2Real-world patterns of maintenance therapy after allogeneic transplant in older adults with acute myeloid leukemia: A Medicare cohort study2026 · 1 citations
  3. 3Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study2025
  4. 4Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis2025
  5. 5Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapse/refractory FLT3-mutated acute myeloid leukemia2026 · 3 citations